Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements

Area of Science:

• Oncology
• Molecular Targeted Therapy
• Non-Small Cell Lung Cancer (NSCLC)

Background:

• Personalized medicine, particularly ALK tyrosine kinase inhibitors (TKIs), has transformed advanced oncogene-addicted NSCLC treatment.
• TKI resistance necessitates novel therapeutic strategies, especially when disease progression is limited to a few sites (oligoprogression).
• Current sequential treatments are often not targeted, highlighting the need for precision in managing resistance.

Purpose of the Study:

• To review current treatment strategies for ALK-rearranged NSCLC with oligoprogression.
• To explore the role of systemic therapy combined with local treatment for progressing sites.
• To identify optimal management approaches for improving survival and quality of life in this patient subset.

Main Methods:

• Comprehensive review of existing literature on ALK-rearranged NSCLC treatment strategies.
• Analysis of retrospective data regarding targeted therapy beyond progression in oligoprogression.
• Inclusion of a real-world clinical case to illustrate management approaches.

Main Results:

• Targeted therapy beyond progression, coupled with local treatment of progressing sites, shows efficacy in oligoprogression.
• A multidisciplinary approach is crucial for integrating systemic and local therapies effectively.
• Specific treatment strategies depend on the site of disease progression.

Conclusions:

• Combining targeted therapy with local interventions offers a promising strategy for ALK-rearranged NSCLC oligoprogression.
• Integrated, multidisciplinary management is essential for maximizing patient survival and quality of life.
• Further research and real-world data are needed to refine optimal treatment paradigms.